Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 6, 2009, Pages

  Hyun, Ju Kim ^a   Moradi, Hamid ^a   Yuan, Jun ^a   Norris, Keith ^b   Vaziri, Nosratola D ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABCA 1 transporter; CD36; Chronic kidney disease; Fatty acid synthase; Lipid metabolism; LXR; Nuclear transcription factors sterol regulatory element binding proteins; PPAR ; Scavenger receptors

Indexed keywords

ABC TRANSPORTER; ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A OXIDASE; CARBOHYDRATE BINDING PROTEIN; CUBILIN; FATTY ACID BINDING PROTEIN; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MEGALIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; REGULATOR PROTEIN; SCAVENGER RECEPTOR A; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; KIDNEY TUBULE ABSORPTION; KIDNEY TUMOR; LIPID STORAGE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEINURIA; RAT; REGULATORY MECHANISM; SHAM PROCEDURE; UPREGULATION; UREMIA;

EID: 66449113034     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90761.2008     Document Type: Article

References (60)

1. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24: 46-53, 2004. (Pubitemid 38258276)
2. Baines RJ, Brunskill NJ. The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol 110: e67-e71, 2008.
3. Barbier O, Torra P, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22: 717-726, 2002. (Pubitemid 34517781)
4. Bengoechea-Alonso MT, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol 19: 215-222, 2007. (Pubitemid 46386402)
5. Bocan TM, Krause BR, Rosebury WS, Mueller SB, Lu X, Dagle C, Major T, Lathia C, Lee H. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 20: 70-79, 2000. (Pubitemid 30048348)
6. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T, Jurgens A, Kovacic V, Van Marck EA, De Broe ME, Verpooten GA. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 59: 2346-2356, 2001. (Pubitemid 32467629)
7. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci USA 96: 11041-11048, 1999. (Pubitemid 29487324)
8. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340, 1997. (Pubitemid 27220877)
9. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95: 89-100, 2002.
10. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 275: 12633-12638, 2000. (Pubitemid 30241412)
11. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 276: 13750-13755, 2001. (Pubitemid 37391749)
12. DeBose-Boyd RA. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res 18: 609-621, 2008.
13. De Winther M, Hofker M. Scavenging new insights into atherogenesis. J Clin Invest 105: 1039-1041, 2000. (Pubitemid 30217686)
14. Febbraio M, Silverstein RL. CD36: implications in cardiovascular disease. Int J Biochem Cell Biol 39: 2012-2030, 2007. (Pubitemid 47376825)
15. Folch J, Lee M, Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 479-509, 1957.
16. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 104: 503-516, 2001. (Pubitemid 32201946)
17. Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int 60: 14-30, 2001. (Pubitemid 32587535)
18. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 15: 2801-2815, 2004. (Pubitemid 41103389)
19. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim R. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002.
20. Igoudjil A, Massart J, Begriche K, Descatoire V, Robin M, Frometry B. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes. Toxicol in Vitro 22: 887-898, 2008.
21. Ishii S, Iizuka K, Miller BC, Uyeda K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc Natl Acad Sci USA 101: 15597-15602, 2004. (Pubitemid 39473533)
22. Ishigaki N, Yamamoto T, Shimizu Y, Kobayashi K, Yatoh S, Sone H, Takahashi A, Suzuki H, Yamagata K, Yamada N, Shimano H. Involvement of glomerular SREBP-1c in diabetic nephropathy. Biochem Biophys Res Commun 364: 502-508, 2007. (Pubitemid 350026495)
23. Jiang T, Liebman SE, Lucia S, Li J, Levi M. Role of altered lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int 68: 2608-2620, 2005. (Pubitemid 43251007)
24. Jiang T, Liebman SE, Scott Lucia M, Phillips CL, Levi M. Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol 16: 2385-2394, 2005. (Pubitemid 41725056)
25. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Scott Lucia M, Li J, Levi M. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280: 32317-32325, 2005. (Pubitemid 41361841)
26. Johnson ACM, Yabu JM, Hanson S, Shah VO, Zager RA. Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. Am J Pathol 163: 313-320, 2003. (Pubitemid 36042010)
27. Kataoka H, Kume N, Miyamoto S, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectin-like oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 99: 3110-3117, 1999. (Pubitemid 29289075)
28. Kim HJ, Vaziri ND. Sterol regulatory element-binding proteins, liver X receptor, ABCA1 transporter, CD36, scavenger receptors A1 and B1 in nephrotic kidney. Am J Nephrol 29: 607-614, 2009.
29. Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101: 2889-2895, 2000. (Pubitemid 30415877)
30. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 20: 1116-1122, 2000. (Pubitemid 30207591)
31. Lusis AJ. Atherosclerosis. Nature 407: 233-241, 2000.
32. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res 69: 36-45, 2006. (Pubitemid 41814809)
33. Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J. Mechanism by which a novel non-thiozolidinedione peroxisome proliferator-activated receptor agonist, FK614, ameliorates insulin resistance in Zucker fatty rats. Diabetes Obes Metab 9: 369-378, 2007. (Pubitemid 46502057)
34. Moestrup SK, Nielsen LB. The role of the kidney in lipid metabolism. Curr Opin Lipidol 16: 301-306, 2005. (Pubitemid 40839759)
35. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 26: 1702-1711, 2006. (Pubitemid 44305322)
36. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309-1311, 1982. (Pubitemid 13240921)
37. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of HDL in chronic kidney disease. Transl Res 153: 77-85, 2009.
38. Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M. Decreased peroxisome proliferator-activated receptor α gene expression is associated with dyslipidemia in a rat model of chronic renal failure. Metabolism 56: 1714-1718, 2007. (Pubitemid 350060939)
39. Naito C, Yamanaka T. Lipid peroxides in atherosclerotic diseases. Jpn J Geriatrics 15: 187-191, 1978.
40. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 99: 1031-1043, 2006. (Pubitemid 44729927)
41. Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer MD. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor α. Diabetes 55: 885-893, 2006. (Pubitemid 44100160)
42. Proctor G, Jiang T, Iwahashi M, Wang Z, Li J, Levi M. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55: 2502-2509, 2006. (Pubitemid 44871150)
43. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 19: 65-73, 2008.
44. Sakurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T. Activation of transcription factor NF-κB in experimental glomerulonephritis in rats. Biochim Biophys Acta 1316: 132-138, 1996. (Pubitemid 26193966)
45. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14: 281-287, 2003. (Pubitemid 36688207)
46. Storch J, Thumser AEA. The fatty acid transport function of fatty acid-binding proteins. Biochim Biophys Acta 1486: 28-44, 2000. (Pubitemid 30336790)
47. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277: 18919-18927, 2002. (Pubitemid 34952453)
48. Takemura T, Yashioka K, Aya N, Murakami K, Matumoto A, Itakura H, Kodama T, Suzuki H, Maki S. Apolipoproteins and lipoprotein receptors in glomeruli in human kidney disease. Kidney Int 43: 918-927, 1993. (Pubitemid 23105228)
49. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17: 985-993, 2003. (Pubitemid 36683707)
50. Vaziri ND. Oxidative stress in chronic renal failure: the nature, mechanism and consequences. Semin Nephrol 24: 469-473, 2004. (Pubitemid 39361056)
51. Vaziri ND, Bai Y, Ni Z, Quiroz Y, Rodriguez-Iturbe B. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 323: 85-93, 2007. (Pubitemid 47443257)
52. Vaziri ND, Dang B, Zhan CD, Liang K. Downregulation of hepatic acyl-CoA: diglycerol acyltransferase (DGAT) in chronic renal failure. Am J Physiol Renal Physiol 287: F90-F94, 2004. (Pubitemid 38780587)
53. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 14: 1462-1466, 1999. (Pubitemid 29241738)
54. Vaziri ND, Liang K, Parks JS. Downregulation of lecithin:cholesterol acyltransferase (LCAT) in chronic renal failure. Kidney Int 59: 2192-2196, 2001. (Pubitemid 32467611)
55. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol 287: F1038-F1043, 2004. (Pubitemid 39391101)
56. Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell 77: 53-62, 1994. (Pubitemid 24184687)
57. db/db mice with type 2 diabetes. Diabetes 54: 2328-2335, 2005.
58. Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X, Zhu Y, Breyer MD, Guan Y. Liver X receptor-α mediates cholesterol efflux in glomerular mesangial cells. Am J Physiol Renal Physiol 287: F886-F895, 2004. (Pubitemid 39391085)
59. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, Goldstein JL, Brown MS. Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 110: 489-500, 2002. (Pubitemid 35232292)
60. Zager RA, Johnson ACM, Hanson SY, Shah VO. Acute tubular injury causes dysregulation of cellular cholesterol transport proteins. Am J Pathol 163: 313-320, 2003. (Pubitemid 36759616)